10-Q · August 5, 2026
BeOne delivered a strong Q2: revenue grew 29.6% to $1.705 billion, diluted GAAP EPS increased to $2.05 per ADS from $0.84, and operating income rose to $325.0 million from $87.9 million. Growth was overwhelmingly led by…
Earnings analysis · 10-Q
ONC earnings analysis
Filed November 5, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not contain the income statement, segment results, balance-sheet detail, or capital-expenditure data needed to assess revenue, margins, EPS, or free cash flow. The available disclosures…
Read full summary
The provided 10-Q excerpt does not contain the income statement, segment results, balance-sheet detail, or capital-expenditure data needed to assess revenue, margins, EPS, or free cash flow. The available disclosures show stronger operating cash flow of $1,173 million for the first nine months of 2026 versus $710 million in the prior-year period and substantial liquidity of $5.8 billion in cash and cash equivalents. However, updated risks around U.S. pricing reforms, tariffs, AI-enabled cybersecurity threats and BRUKINSA patent challenges remain material, supporting a neutral assessment based on the filing excerpt.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Operating cash flow improved materially
Operating cash flow was approximately $1,173 million for the nine months ended September 30, 2026, up from $710 million in the comparable 2025 period, an increase of approximately $463 million or 65%.
-
Strong liquidity position
Cash and cash equivalents totaled $5.8 billion at September 30, 2026, with an additional $85.2 million of restricted cash; management believes liquidity is sufficient for projected operating requirements for at least the next 12 months.
-
Accumulated deficit narrowed
Accumulated deficit declined to $7.5 billion at September 30, 2026 from $8.3 billion at December 31, 2025, a reduction of approximately $0.8 billion.
-
No material control changes reported
Management reported that disclosure controls were effective at a reasonable assurance level as of September 30, 2026, and that there were no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
U.S. drug-pricing reforms could reduce revenue
The updated pricing and reimbursement risk cites proposed GLOBE and GUARD Medicare models with proposed seven-year testing periods beginning January 1, 2027. The filing states these models could require additional rebates, while U.S. sales represent a substantial portion of revenue, creating potential pressure on net revenue and margins.
-
Tariff and geopolitical exposure
The updated international-market risk states that Section 232 tariffs imposed beginning in September 2026 ranged from 10% to 100% on certain patented pharmaceutical products and inputs. Although the company entered an onshoring agreement in August 2026 securing an exemption, the filing says the scope and duration of future tariffs remain uncertain.
-
AI-enabled cyber and data-security risk
The updated cybersecurity and AI risks identify increasingly sophisticated attacks, including ransomware, deepfakes, prompt injection, model hallucinations and autonomous AI-agent exploits. The filing states that the company and third-party collaborators have experienced cyber-based attacks, although no past incident was individually or collectively material; a future breach could disrupt research, clinical, manufacturing or commercialization activities.
-
BRUKINSA generic litigation risk
BRUKINSA faces generic-entry litigation after Zydus filed an ANDA challenging certain Orange Book patents, prompting BeOne to file suit on February 25, 2026. While the composition-of-matter patent remains intact through 2034 according to the filing, the outcome of the asserted-patent litigation could affect product exclusivity and revenue.
Management's outlook
The provided 10-Q excerpt does not include quantitative revenue or EPS guidance. Management states it believes cash and cash equivalents are sufficient to meet projected operating requirements for at least the next 12 months, but does not provide a numeric outlook for revenue, earnings, margins, or capital spending.
Earlier filings 4
10-Q · May 6, 2026
BeOne Medicines Ltd. reported strong Q1 2026 financial results, with total revenue of $1.51 billion, a 35% increase year-over-year, driven largely by successful sales of BRUKINSA, which saw a 38% revenue growth. The…
10-K · February 26, 2026
BeOne Medicines reported strong 2025 results with total revenue of approximately $5.3 billion (up ~40.2% year-over-year), GAAP net income of $286.9 million, and positive free cash flow of $941.7 million. Commercial…
10-Q · November 6, 2025
BeOne Medicines (filed as BeOne/previously BeiGene) reported a strong quarter with total revenues of $1,412,284 (in thousands) vs $1,001,599 in the year-ago quarter and returned to profitability with net income of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.